One speech platform, many CNS programs
Speech recruits memory, word-finding, articulation, prosody and timing at once. Those domains are affected across CNS disease, which is why one measurement platform serves several indications.
We have programs in Alzheimer's, Parkinson's, Huntington's and ALS. In depression and in the behavioural symptoms of dementia, the endpoint is a rating produced from an interview. Where that interview is recorded, a second reading attaches to the audio you already hold.
Why one platform transfers across indications
Producing a sentence takes planning, lexical retrieval, breath support, laryngeal control and articulation: cognitive and motor systems working together. CNS conditions disturb different parts of that chain, but they disturb the same measurable chain.
What changes between indications is which domains carry the signal; the architecture stays the same.
Six program areas
Each mapped to the endpoints its trials already run.
Alzheimer's disease
Readings on cognitive tests such as the MMSE and MoCA, followed between visits.
Parkinson's disease
Readings on the MDS‑UPDRS speech item, followed between visits.
Huntington's disease
Speech and language change from the premanifest stage, mapped to the cUHDRS spoken components.
ALS
Readings on the ALSFRS‑R speech item, followed between visits.
DM1 and neuromuscular
Articulation, phonation and respiratory support, mapped to the endpoints these trials run.
Depression and BPSD
A second reading of the recorded rating interview.
Your interview recordings hold a second reading
In depression and the behavioural symptoms of dementia, the primary outcome comes from an interview, often recorded.
Where a depression reading attaches
MADRS is scored from a spoken interview, on integer steps. Where that interview is recorded, speech gives a second, consistent reading on the MADRS.
Caregiver and patient, separated by voice
In BPSD trials the rating draws heavily on a caregiver interview.
Working in another indication?
Tell us about the indication and the endpoint your trials run.
Get in touch →